Immune checkpoint inhibitors in cancer therapy
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
Clinical management of metastatic colorectal cancer in the era of precision medicine
F Ciardiello, D Ciardiello, G Martini… - CA: a cancer journal …, 2022 - Wiley Online Library
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a …
LA Diaz, KK Shiu, TW Kim, BV Jensen… - The Lancet …, 2022 - thelancet.com
Background Pembrolizumab has shown improved progression-free survival versus
chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch …
chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch …
Gut microbiota in colorectal cancer development and therapy
Colorectal cancer (CRC) is one of the commonest cancers globally. A unique aspect of CRC
is its intimate association with the gut microbiota, which forms an essential part of the tumour …
is its intimate association with the gut microbiota, which forms an essential part of the tumour …
Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies
Simple Summary The high lethality of colorectal cancer (CRC) is anticipated to continue in
the following decades. Early-stage CRC is entirely treatable with surgery and adjuvant …
the following decades. Early-stage CRC is entirely treatable with surgery and adjuvant …
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
DR Wang, XL Wu, YL Sun - Signal transduction and targeted therapy, 2022 - nature.com
Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …
malignant cells but also an altered immune response. The inhibition and reprogramming of …
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Background Single-agent nivolumab showed durable responses, manageable safety, and
promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 …
promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 …
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade …
is thought to explain their exceptional responsiveness to immune checkpoint blockade …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …